RYTM Live signals | Maximize Profits with Getagraph.com

BUY 136783 min ago

@ $49.81

Issued: 14 Feb 2024 @ 15:43

Return: -23.79%

Previous signal: Feb 13 - 10:40

Previous signal: Sell

Return: 1.67 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity...

Stats
Today's Volume	737 067
Average Volume	569 582
Market Cap	2.31B
EPS	$0 ( 2024-05-07 )
Next earnings date	( $-2.16 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.20
ATR14	$0.0680 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-09	Shulman Joseph	Sell	3 984	Stock Option (right to buy)
2024-05-09	Shulman Joseph	Buy	3 984	Common Stock
2024-05-09	Shulman Joseph	Sell	3 484	Common Stock
2024-05-09	Shulman Joseph	Sell	500	Common Stock
2024-04-14	Mazabraud Yann	Sell	10 375	Common Stock

INSIDER POWER
40.82
Last 100 transactions
Buy: 1 136 201 \| Sell: 472 596

Volume Correlation

Long: 0.13 (neutral)

Short: 0.97 (very strong)

Signal:(70.334) Expect same movement, but be aware

Rhythm Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rhythm Pharmaceuticals Correlation - Currency/Commodity

-0.70
( moderate negative )

-0.57
( weak negative )

0.00
( neutral )

-0.79
( moderate negative )

0.26
( neutral )

0.62
( weak )

Rhythm Pharmaceuticals Financials

Annual	2023
Revenue:	$77.43M
Gross Profit:	$68.13M (87.99 %)
EPS:	$-3.20

FY	2023
Revenue:	$77.43M
Gross Profit:	$68.13M (87.99 %)
EPS:	$-3.20

FY	2022
Revenue:	$23.64M
Gross Profit:	$21.51M (90.98 %)
EPS:	$-3.51

FY	2021
Revenue:	$3.15M
Gross Profit:	$2.56M (81.01 %)
EPS:	$-1.400

Financial Reports:

No articles found.

Rhythm Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.